Praxis Precision Medicines to Report Q4 and Full Year 2025 Results

The biotech company will share its latest financial performance on Thursday, February 13th.

Published on Feb. 9, 2026

Got story updates? Submit your updates here. ›

Praxis Precision Medicines, Inc., a Boston-based biotech company focused on central nervous system disorders, will report its fourth quarter and full year 2025 financial results on Thursday, February 13, 2026.

Why it matters

As a publicly traded company, Praxis Precision Medicines' quarterly and annual financial reports provide important insights into the performance and outlook of the business, which can impact investor sentiment and the stock price.

The details

Praxis Precision Medicines is a leading biotech company developing treatments for central nervous system disorders. The company will report its Q4 2025 and full year 2025 financial results after the market closes on Thursday, February 13, 2026.

  • Praxis Precision Medicines will report Q4 2025 and full year 2025 financial results on Thursday, February 13, 2026.

The players

Praxis Precision Medicines, Inc.

A Boston-based biotech company focused on developing treatments for central nervous system disorders.

Got photos? Submit your photos here. ›

The takeaway

Praxis Precision Medicines' upcoming financial report will provide valuable insights into the company's performance and outlook, which is of interest to investors and the broader biotech industry.